Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Clinical Roundup

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

November 08, 2024
Vol.50 No.42
In Brief

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

October 25, 2024
Vol.50 No.40
In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

October 25, 2024
Vol.50 No.40
Clinical Roundup

Study shows an early blood test can predict survival in metastatic prostate cancer patients

October 11, 2024
Vol.50 No.38
Clinical Roundup

Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

October 04, 2024
Vol.50 No.37
Drugs & Targets

Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC

September 27, 2024
Vol.50 No.36
Clinical Roundup

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

September 20, 2024
Vol.50 No.35
Clinical Roundup

New AI model can prevent unnecessary prostate removals

September 13, 2024
Vol.50 No.34
Clinical Roundup

Study confirms AI outperforms conventional methods for prostate cancer ECE

September 06, 2024
Vol.50 No.33
Clinical Roundup

Updated ArteraAI Prostate Test informs active surveillance decisions for lower-risk prostate cancer

August 09, 2024
Vol.50 No.32

Posts navigation

Previous1…678…16Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Michael Bishop, Nobel-winning cancer researcher, dies at 90
  • Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
  • NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
  • Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
  • FDA issues warning letter to ImmunityBio over misleading claims about cancer drug

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account